Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma
| Autor: | Carol Lorencio, Joan Brunet, Elia Sais, Rut Porta, Joaquim Bosch-Barrera, Josep Maria Sirvent, Javier A. Menendez, Angel Izquierdo, Rafael Rosell |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Pulmonary and Respiratory Medicine
Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Adenocarcinoma of Lung Antineoplastic Agents Adenocarcinoma law.invention Erlotinib Hydrochloride law Internal medicine Intensive care medicine Humans Epidermal growth factor receptor Neoplasm Metastasis Lung cancer Protein Kinase Inhibitors Mechanical ventilation biology business.industry Cancer Middle Aged medicine.disease Respiration Artificial Intensive care unit respiratory tract diseases Surgery Intensive Care Units Treatment Outcome Oncology Quinazolines biology.protein Female Erlotinib Tomography X-Ray Computed business medicine.drug |
| Zdroj: | Lung Cancer. 86:102-104 |
| ISSN: | 0169-5002 |
| Popis: | Background Lung cancer is the most common solid tumor in critically ill cancer patients who are admitted to intensive care units (ICUs). An ICU trial consists of unlimited ICU support for a limited time period. Case report We present the case of a 60-year-old woman with newly diagnosed metastatic lung adenocarcinoma who required mechanical ventilation due to respiratory failure. Empirical erlotinib treatment was administered through a nasogastric feeding tube as part of an ICU trial, which led to a dramatic and durable response. Conclusion Empirical erlotinib should be considered when epidermal growth factor receptor (EGFR) mutations are suspected in ICU newly diagnosed patients with lung adenocarcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect